Join leaders in Boston on March 27 for an exclusive night of networking, insights, and conversation. Request an invite here.
Proscia, a leading provider of digital pathology software, announced today that it has raised $9 million in an extension of its Series C funding round, bringing the total round to $46 million. The funding comes on the heels of Proscia’s recent FDA clearance for its software platform, enabling the company to expand its reach in the U.S. diagnostic market.
The Series C extension was led by Highline Capital Management and Triangle Peak Partners, with participation from existing investors including Alpha Intelligence Capital, Scale Venture Partners, Hitachi Ventures, and others. The funds will be used to accelerate Proscia’s commercial growth and further develop its AI-powered applications for life sciences and diagnostic laboratories.
“We’re so excited about this regulatory clearance. It basically lets us sell our diagnostic products into the U.S. market at a time when the world really needs it,” said David West, cofounder and CEO of Proscia, in an interview with VentureBeat. “This funding will allow us to accelerate our mission of changing the way we diagnose and treat diseases like cancer by unlocking the power of digital pathology data and AI.”
Unlocking the power of digital pathology and AI
Proscia’s software platform is already used by 14 of the top 20 pharmaceutical companies, leveraging massive amounts of pathology image data to drive drug discovery and development. With the FDA clearance, Proscia can now bring its digital pathology solutions to diagnostic labs, addressing the mounting challenges of a global pathologist shortage and rising cancer rates.
VB Event
The AI Impa …
Article Attribution | Read More at Article Source
Join leaders in Boston on March 27 for an exclusive night of networking, insights, and conversation. Request an invite here.
Proscia, a leading provider of digital pathology software, announced today that it has raised $9 million in an extension of its Series C funding round, bringing the total round to $46 million. The funding comes on the heels of Proscia’s recent FDA clearance for its software platform, enabling the company to expand its reach in the U.S. diagnostic market.
The Series C extension was led by Highline Capital Management and Triangle Peak Partners, with participation from existing investors including Alpha Intelligence Capital, Scale Venture Partners, Hitachi Ventures, and others. The funds will be used to accelerate Proscia’s commercial growth and further develop its AI-powered applications for life sciences and diagnostic laboratories.
“We’re so excited about this regulatory clearance. It basically lets us sell our diagnostic products into the U.S. market at a time when the world really needs it,” said David West, cofounder and CEO of Proscia, in an interview with VentureBeat. “This funding will allow us to accelerate our mission of changing the way we diagnose and treat diseases like cancer by unlocking the power of digital pathology data and AI.”
Unlocking the power of digital pathology and AI
Proscia’s software platform is already used by 14 of the top 20 pharmaceutical companies, leveraging massive amounts of pathology image data to drive drug discovery and development. With the FDA clearance, Proscia can now bring its digital pathology solutions to diagnostic labs, addressing the mounting challenges of a global pathologist shortage and rising cancer rates.
VB Event
The AI Impa …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]